Correction to Tuesday's ADR Shares Story
September 10 2014 - 1:39PM
Dow Jones News
"ADR Shares End Lower; Novo Nordisk Shares Trade Actively" on
Tuesday at 5:29 p.m. EDT incorrectly said Novo Nordisk received a
favorable view from a U.S. Food and Drug Administration advisory
committee on its diabetes drug Saxenda. Rather, documents released
ahead of the FDA Advisory Committee review suggested Saxenda is
effective for weight loss.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024